Posted by Michael Wonder on 03 Dec 2020
Moleculin announces FDA approves 3 rare paediatric disease designations for WP1066
1 December 2020 - Moleculin Biotech today announced that the US FDA has approved its request for a rare paediatric disease designation for its drug candidate WP1066.
The designation entitles Moleculin to receive a transferrable priority review voucher upon new drug approval for each of three indications, including diffuse intrinsic pontine glioma, medulloblastoma and atypical teratoid rhabdoid tumour.
